Patient and caregiver time burden associated with anaemia treatment in different patient populations

Supportive Care in Cancer

Volumn 14, Issue 12, 2006, Pages 1195-1204

  Houts, Arthur C ^a,c   Loh, Geoffrey A ^b   Fortner, Barry V ^a   Kallich, Joel D ^b  

^a Supportive Oncology Services and Accelerated Community Oncology   (United States)

^b AMGEN INC   (United States)

^c ACORN   (United States)

Author keywords

Anaemia; Chemotherapy; Darbepoetin alfa; Epoetin alfa; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGE; AGED; ANEMIA; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CAREGIVER; CAREGIVER BURDEN; FEMALE; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TRAVEL; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CAREGIVERS; CROSS-SECTIONAL STUDIES; EMPLOYMENT; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; REGRESSION ANALYSIS; TIME FACTORS;

EID: 33748796824     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0075-0     Document Type: Article

References (26)

1. Moore KA (1999) Breast cancer patients' out-of-pocket expenses. Cancer Nurs 22:389-396
2. Birgegard G, Aapro MS, Bokemeyer C et al (2005) Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 68(Suppl 1):3-11
3. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1692
4. Fortner B, Tauer K, Zhu L, Ma L, Schwartzberg LS (2004) The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver: a national survey. Community Oncol 1:211-217
5. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63-74
6. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95:155-163
7. National Comprehensive Cancer Network (2003) NCCN practice guidelines in oncology: cancer and treatment-related anemia. Version 1
8. Curt GA, Breitbart W, Cella D et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5:353-360
9. Glaspy JA, Tchekmedyian NS (2002) Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Williston Park) 16(10 Suppl 11):23-29
10. Littlewood TJ (2002) Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy. Front Radiat Ther Oncol 37:34-37
11. Mirtsching BC, Beck JT, Charu V et al (2003) Darbepoetin alfa administered every two weeks (Q2W) reduces chemotherapy-induced anemia (CIA) to the same extent as recombinant human erythropoietin (rHuEPO) but with lessfrequent dosing. Proc Am Soc Clin Oncol 22:732, Abstract 2944
12. Meehan KR, Tchekmedyian NS, Ciesla G, Kallich J, Erder H, Smith R (2003) The burden of weekly epoetin alfa injections to patients and their caregivers. Proc Am Soc Clin Oncol 22:543
13. Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB (1999) Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 16(5 Pt 1):459-472
14. Houts PS, Lipton A, Harvey HA et al (1984) Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer 53:2388-2392
15. Guidry JJ, Aday LA, Zhang D, Winn RJ (1997) Transportation as a barrier to cancer treatment. Cancer Pract 5:361-366
16. Moore K, Fortner B, Okon T (2003) The impact of medical visits on patients with cancer and their caregivers. Proceedings of the 28th Annual Congress of the Oncology Nursing Society, Denver, May 1-4, Abstract 73
17. Payne S, Jarrett N, Jeffs D (2000) The impact of travel on cancer patients' experiences of treatment: a literature review. Eur J Cancer Care (Engl) 9:197-203
18. Zip-codes.com. The Zip Code Database List. http://www.zip-codes.com/ Accessed August 2005
19. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W (1998) Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 12:369-377
20. Curt GA (2000) Impact of fatigue on quality of life in oncology patients. Semin Hematol 37(4 Suppl 6):14-17
21. Tchekmedyian NS, Kallich J, McDermott A, Fayers P, Erder MH (2003) The relationship between psychologic distress and cancer-related fatigue. Cancer 98:198-203
22. Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220
23. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299
24. Vansteenkiste J (2004) Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer 12:253-262
25. Canby JB 4th (1995) Applying activity-based costing to healthcare settings. Healthc Financ Manage 49(50-52):54-56
26. Gabram SG, Mendola RA, Rozenfeld J, Gamelli RL (1997) Why activity-based costing works. Physician Exec 23:31-37